Our subsidiary Aumed Pharma a.s. is launching a revolutionary bacteriophage-based product in the fight against problematic skin. Phage Glow is...
Our subsidiary Aumed Pharma is launching a new website (www.aumedpharma.cz) where you can purchase our specially developed nutritional supplements and...
A representative of AUMED participated in the meeting to establish the association Czech Antibiotic Resistance Platform (CZEPAR). The course of...
AUMED, a.s. successfully completed the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As part of the project,...
AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As...
AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a...
AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company....
AUMED, a.s. successfully completed a multi-year project of the research and development support program of the Ministry of Industry and...
AUMED, a.s. received a grant in the Operational Program Enterprise and Innovation for Competitiveness under the Innovation Call – Innovation...
AUMED, a.s. launches its own self-sampling set based on the principle of gargling of the oral cavity and pharynx. The...
AUMED a.s. received support for the project PRODUCTION OF DIAGNOSTIC KIT FOR COVID-19 ON THE LAMP PRINCIPLE within the TECHNOLOGY...
AUMED, a.s. collaborated on the development of a new self-sampling set based on the principle of gargling of the oral...
AUMED a.s. offers for companies a comprehensive solution for preventive testing of the SARS-CoV-2 virus (COVID-19). We provide sampling and...
AUMED a.s. is involved in the fight against the Covid-19 pandemic. In cooperation with Protean s.r.o. and Institute of Molecular and...
This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “Transfer factor – research and...
This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “RESEARCH AND DEVELOPMENT OF A...
The project of innovative vaccine against whooping cough is in the terminal phase. The priority is the research and development...
AUMED is preparing the production of a mass-produced medical product. Under the contract manufacturing regime, AUMED wants to become a...
As part of the 4th public tender in the TRIO program, AUMED has a project for a new version of...
Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical formProduction of diagnostic kit for covid-19 on the lamp principleTFI Transfer Factor – Medicine
and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
